Route to three-dimensional fragments using diversity-oriented synthesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 17, 2011, Pages 6799-6804

  Hung, Alvin W ^a   Ramek, Alex ^b   Wang, Yikai ^b   Kaya, Taner ^a   Wilson, J Anthony ^a   Clemons, Paul A ^a   Young, Damian W ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Library development; Probe discovery

Indexed keywords

AROMATIC COMPOUND; LIGAND;

ARTICLE; CHEMICAL ANALYSIS; DIVERSITY ORIENTED SYNTHESIS; DRUG RESEARCH; FRAGMENT BASED DRUG DISCOVERY; HIGH THROUGHPUT SCREENING; MOLECULAR LIBRARY; MOLECULE; PRIORITY JOURNAL; STEREOCHEMISTRY; SYNTHESIS;

DATABASES, FACTUAL; DRUG DESIGN; HYDROCARBONS, AROMATIC;

EID: 79955566051     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1015271108     Document Type: Article

References (38)

1. Schreiber SL (2009) Organic chemistry: Molecular diversity by design. Nature 457:153-154.
2. Schreiber SL (2005) Small molecules: The missing link in the central dogma. Nat Chem Biol 1:64-66.
3. Stockwell BR (2004) Exploring biology with small organic molecules. Nature 432:846-854.
4. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29-40. (Pubitemid 46020284)
5. Congreve M, Chessari G, Tisi D, Woodhead AJ (2008) Recent developments in fragment-based drug discovery. J Med Chem 51:3661-3680. (Pubitemid 351956496)
6. Murray CW, Rees DC (2009) The rise of fragment-based drug discovery. Nat Chem 1:187-192.
7. Chessari G, Woodhead AJ (2009) From fragment to clinical candidate-a historical perspective. Drug Discov Today 14:668-675.
8. Fink T, Reymond J-L (2007) Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: Assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J Chem Inf Model 47:342-353. (Pubitemid 46615939)
9. Ciulli A, Abell C (2007) Fragment-based approaches to enzyme inhibition. Curr Opin Biotechnol 18:489-496.
10. Hung AW, et al. (2009) Application of fragment growing and fragment linking to the discovery of inhibitors of mycobacterium tuberculosis pantothenate synthetase. Angew Chem Int Ed 48:8452-8456.
11. Blundell TL, Jhoti H, Abell C (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 1:45-54. (Pubitemid 37361403)
12. Galloway WRJD, Isidro-Llobet A, Spring DR (2010) Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. Nat Commun 1:80.
13. Hajduk PJ, Galloway WRJD, Spring DR (2011) Drug discovery: A question of library design. Nature 470:42-43.
14. Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: Strategic advances and lessons learned. Nat Rev Drug Discov 6:211-219. (Pubitemid 46344625)
15. Coyne AG, Scott DE, Abell C (2010) Drugging challenging targets using fragmentbased approaches. Curr Opin Chem Biol 14:299-307.
16. Schreiber SL (2000) Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287:1964-1969.
17. Burke MD, Schreiber SL (2004) A planning strategy for diversity-oriented synthesis. Angew Chem Int Ed 43:46-58. (Pubitemid 38063470)
18. Marcaurelle LA, et al. (2010) An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: Discovery of macrocyclic histone deacetylase inhibitors. J Am Chem Soc 132:16962-16976.
19. Stanton BZ, et al. (2009) A small molecule that binds hedgehog and blocks its signaling in human cells. Nat Chem Biol 5:154-156.
20. Spiegel DA, Schroeder FC, Duvall JR, Schreiber SL (2006) An oligomer-based approach to skeletal diversity in small-molecule synthesis. J Am Chem Soc 128:14766-14767. (Pubitemid 44851590)
21. Nielsen TE, Schreiber SL (2008) Towards the optimal screening collection: A synthesis strategy. Angew Chem Int Ed 47:48-56.
22. Congreve M, Carr R, Murray C, Jhoti H (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today 8:876-877.
23. Huang P-Q (2006) Asymmetric synthesis of hydroxylated pyrrolidines, piperidines and related bioactive compounds: From N-acyliminium chemistry to N-α-carbanion chemistry. Synlett 8:1133-1149.
24. Harris PWR, Brimble MA, Gluckman PD (2003) Synthesis of cyclic proline-containing peptides via ring-closing metathesis. Org Lett 5:1847-1850. (Pubitemid 37161940)
25. Seebach D, Boes M, Naef R, Schweizer WB (1983) Alkylation of amino acids without loss of the optical activity: Preparation of á-substituted proline derivatives. A case of self-reproduction of chirality. J Am Chem Soc 105:5390-5398.
26. Wang H, Germanas JP (1999) 4-Alkyl-2-trichloromethyloxazolidin-5-ones: Valuable precursors to enantiomerically pure C- and N-protected α-alkyl prolines. Synlett 1999:33-36. (Pubitemid 29093052)
27. Harris PWR, Brimble MA (2006) Synthesis of macrocyclic analogues of the neuroprotective agent glycyl-l-prolyl-l-glutamic acid (GPE). Org Biomol Chem 4:2696-2709. (Pubitemid 44034216)
28. Hoffmann T, Lanig H, Waibel R, Gmeiner P (2001) Rational molecular design and EPC synthesis of a type VI β-turn inducing peptide mimetic. Angew Chem Int Ed 40:3361-3364. (Pubitemid 32916599)
29. Subirós-Funosas R, Prohens R, Barbas R, El-Faham A, Albericio F (2009) Oxyma: An efficient additive for peptide synthesis to replace the benzotriazole-based HOBt and HOAt with a lower risk of explosion. Chem Eur J 15:9394-9403.
30. Zhou A, Hanson PR (2008) Synthesis of Sultam scaffolds via intramolecular oxa-Michael and diastereoselective Baylis-Hillman reactions. Org Lett 10:2951-2954.
31. Hong SH, Day MW, Grubbs RH (2004) Decomposition of a key intermediate in ruthenium-catalyzed olefin metathesis reactions. J Am Chem Soc 126:7414-7415. (Pubitemid 38781455)
32. McNaughton BR, Bucholtz KM, Camaaño-Moure A, Miller BL (2005) Self-selection in olefin cross-metathesis: The effect of remote functionality. Org Lett 7:733-736.
33. Lovering F, Bikker J, Humblet C (2009) Escape from flatland: Increasing saturation as an approach to improving clinical success. J Med Chem 52:6752-6756.
34. Ritchie TJ, Macdonald SJF (2009) The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design? Drug Discov Today 14:1011-1020.
35. Clemons PA, et al. (2010) Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles. Proc Natl Acad Sci USA 107:18787-18792.
36. Irwin JJ, Shoichet BK (2005) ZINC - A free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177-182.
37. Carr RAE, Congreve M, Murray CW, Rees DC (2005) Fragment-based lead discovery: Leads by design. Drug Discov Today 10:987-992. (Pubitemid 40967047)
38. Sauer WHB, Schwarz MK (2003) Molecular shape diversity of combinatorial libraries: A prerequisite for broad bioactivity. J Chem Inf Comput Sci 43:987-1003.